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Abstract. The interaction between tumor cells and extracel-
lular matrix (ECM) proteins influences cell migration and 
the invasive behavior of cancer cells. In this study, we provide 
experimental evidence that collagen I and fibronectin affect 
ovarian cancer cell migration. In vitro wound healing assays 
and transwell migration assays were used to measure both total 
wound healing and directionality of individually migrating 
OV2008 and C13 ovarian cancer cells on glass, collagen I 
and fibronectin. Involvement of p21-activated kinase 2 
(PAk2) in the motility of these cell lines was investigated 
using a chemical inhibitor as well as siRNA transfection. 
Culturing ovarian cancer cells on collagen type I (COLL) 
increased the migratory ability of OV2008 and C13 cells 
by increasing the directional migration of cells. In contrast, 
fibronectin (FN) decreased the migratory ability of OV2008 
cells by reducing their ability to migrate directionally. 
When both cell lines are cultured on COLL and treated with 
increasing concentrations of a PAK inhibitor (IPA-3), there 
is a dose-dependent response such that there is a decrease 
in migration with an increase in inhibitor concentration. 
Further experiments utilizing PAK2 knockdown via siRNA 
transfection demonstrated significantly reduced migration 
of OV2008 cells on COLL as compared to those receiving 
control siRNA. In conclusion, our results indicate that FN 
and COLL affect the motility of the selected ovarian cancer 
cells lines and the effect of COLL is likely mediated, at least 
in part, by PAK2. A better understanding of the molecular 
events that contribute to tumor invasion and metastasis is 
crucial for developing novel treatment strategies to improve 
the long-term survival of women with ovarian cancer. As 
PAk2 is involved in motility, it should be further explored 
as a pro-metastatic gene in ovarian cancer.
Introduction
Cell migration pathways play significant roles in a variety of 
physiological processes that can be ʻhijackedʼ by cancer cells 
and thus, increase the metastatic potential of the disease and 
increase the incidence of cancer-related deaths (1). Regardless 
of when it occurs, the dissemination of tumor cells from the 
primary tumor is the principle reason for the mortality and 
morbidity of cancer patients. This appears to be particularly 
important for ovarian surface epithelial (OSE) cancer, which 
is often diagnosed only after cells have been released into the 
peritoneal cavity. Therefore, investigation into the molecular 
mechanisms of tumor cell motility has been intensified. 
Therapies that specifically target the motility of tumor cells 
could significantly improve cancer treatment by removing the 
threat of systemic disease and decreasing the sole dependence 
on cytotoxic therapeutics with detrimental side-effects (2).
The dynamic interaction between a cell and extracellular 
matrix (ECM) proteins influences cell migration and the inva-
sive behavior of cancer cells. These proteins influence both 
the motility and migratory capacity of normal cells, and the 
metastasis of tumor cells. Although the extracellular matrix 
was initially perceived as a barrier to tumor cell dissemina-
tion, it is becoming evident that the architecture and the matrix 
composition of the microenvironment can promote tumor cell 
dissemination. Specifically ECM proteins have been shown 
to influence movement in ovarian cancer cells through inter-
action with integrins (3).
As groups, integrins mediate adhesion and mechano-
transduction to extracellular ligands via α2β1 integrin 
predominantly binding to fibrillar collagen; αvβ3, αvβ1 
and α5β1 interacting with fibronectin; and α3β1 and α6β1 
engaging with laminin (4). After associating with ligands, 
the cytoplasmic tails of integrins interact with cytoskel-
etal adaptor proteins (5,6). Adaptor and mechanosensing 
modulator proteins engage with the actin cytoskeleton and 
trigger signaling to protein kinases, including focal adhe-
sion kinase (FAK) and Src (5,7,4). Downstream integrin 
effectors further include the small GTPases Rac and Rho, 
which reinforce cell protrusion and rear contraction (8). 
The Rho-family GTPases have been directly linked to 
motility and protrusion formation through their ability to 
activate the signaling targets that regulate actin cytoskel-
eton modification (9).
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Cell migration can be subdivided into random motility 
and directed migration, the latter indicating whether a cell is 
able to maintain a single direction of migration for prolonged 
periods of time (10). Directional motility requires polariza-
tion, and maintaining polarity determines persistence with 
which a cell moves directionally. Morphological polarization 
is a consequence of an internal asymmetry in distribution of 
signaling molecules and cellular structures, primarily cyto-
skeletal (11). External stimuli are not necessarily required to 
trigger and maintain polarity, although they can contribute 
and shift equilibria in favor of polarized states. Chemotactic 
and haptotactic gradients serve as external guides by keeping 
up cell polarity and reducing the probability of changing 
direction. Polarized motility is governed by organization of a 
leading edge in the direction of cell movement. The leading 
edge is stabilized by the formation of new focal adhesions 
or cell-ECM contact sites (12). While directional cell migra-
tion facilitates the coordinated movement of cells during the 
development and tissue repair, the pathways involved with 
regulating the interplay between the extracellular environ-
ment, the actin cytoskeleton and the plasma membrane that 
result in directional movement remain inadequately under-
stood.
It is believed that intracellular signaling, often mediated at 
the leading edge by the Rho family of small GTPases, operates 
at each step of the cell motility cycle to promote directional 
migration by regulating leading edge formation. Among the 
downstream targets of the Rho family of small GTPases, PAK 
(p21-activaed kinases) serine/threonine protein kinases have 
been implicated as effectors of cell motility. These kinases are 
subdivided into two groups, PAK1-3 (group I) and PAK4-6 
(group II). The group I isoforms contain an autoinhibitory 
domain (PID) which is absent in group II PAK proteins (13). 
The group I PAKS share a p21-binding domain (PBD), a 
serine/threonine kinase domain, an acidic region and multiple 
proline-rich regions that serve as binding sites for SH3 
domain-containing proteins. PAk kinases were first identified 
in screens for Rac and Cdc42 effectors (14).
Several targets of PAks are directly implicated in regul-
ating cytoskeletal dynamics, including LIM domain kinase 1 
(15), which phosphorylates and inactivates cofilin, an F-actin-
severing and -depolymerizing protein, or myosin light chain 
(16) and mLC kinase (17), which control myosin contractility. 
PAks are also involved in the reorganization of the focal 
adhesions (18,19). So it appears logical that PAK(s) could play 
important role(s) in modulating the ability of cancer cells to 
move and metastasize. A number of human breast cancer lines 
exhibit constitutively elevated PAk1 and PAk2 activity, in 
some cases associated with the presence of an activated Rac 
GTPase (20) and PAk activity has been linked to tumor inva-
siveness and motility of a variety of human cancer cell lines 
(21).
A better understanding of motility and its role in cancer 
metastasis is crucial to reducing the number of annual deaths 
due to metastatic disease. Therefore, the experiments reported 
herein were designed to test the hypothesis that ECM proteins 
(specifically collagen I and fibronectin abundant in the perito-
neal mesenteries) are important in ovarian cancer metastasis, 
facilitating cellular motility. We identified PAk2 as a possibly 
important mediator of ovarian cancer cell migration on ECM.
Materials and methods
Materials. Fetal bovine serum (FbS) was obtained from 
Innovative Research (Novi, mI). RPmI-1640 media with 
L-glutamine and without sodium bicarbonate was purchased 
from HyClone Laboratories, Inc. (Logan, UT). CellTiter 96® 
AQueousOne Solution Cell Proliferation Assay (mTS) was 
purchased from Promega (Madison, WI). Antibiotic antimycotic 
solution (100X) stabilized, with 10,000 units penicillin, 10 mg 
streptomycin and 25 µg amphotericin B per ml (PSA) was 
obtained from mediatech, Inc. (manassas, vA). human plasma 
fibronectin and bovine collagen type I was ordered from 
bD biosciences (Franklin Lakes, NJ). Sodium bicarbonate, 
hEPES and trypsin solution from porcine pancreas were 
purchased from Sigma-Aldrich (St. Louis, MO). T-25 cm2 cell 
culture flasks were produced by Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA).
Cell lines and culture conditions. The cisplatin-sensitive cell 
line, Ov2008, was derived from ovarian serous cystadeno-
carcinoma from a patient without prior chemotherapy (22); 
and its resistant variant, C13, originated from in vitro cisplatin 
challenges of OV2008 cells (23). These cells were acquired as 
a gift from Dr Barbara Vanderhyden (University of Ottawa, 
Canada). The Ov2008 and C13 cell lines were maintained in 
RPmI-1640 (1x) medium, supplemented with 10% fetal bovine 
serum (FbS) and 1% PSA, sodium bicarbonate (24 mm) and 
HEPES (10 mM). All cell cultures were maintained at 37˚C in 
a humidified atmosphere with 5% CO2.
All wound healing assays were performed in modified 
35-mm cell culture dishes. These dishes were created by 
punching a hole in the bottom of the dish followed by adher-
ence of a 22-mm2 glass cover slip (Corning) to the bottom of 
the dish. These dishes were baked at 60˚C for 2 days before 
being soaked overnight in a CytoClean solution. The dishes 
were then rinsed, dried and sterilized via exposure to UV light 
for 2.5 h.
Culture of ovarian cancer cell lines on collagen I and fibro-
nectin. The substrata that were used in the current investigation 
were selected to represent some of the different types of ECm 
that OSE cells may contact, in vivo, when disseminated into 
the peritoneal cavity. Glass cover slips were coated with extra-
cellular matrix proteins by suspending the ECM proteins in a 
solvent (fibronectin in PBS, collagen I in 0.1 N HCl). Collagen 
was used as a thin coating at 10 µg/cm2 and fibronectin was 
applied at a 5-µg/cm2 as per the manufacturer's recommenda-
tions. The ECm solution was then added to the cover slips and 
allowed to incubate for 1 h at room temperature. The cover 
slips were then quickly rinsed with PBS before plating the 
cells onto the coated cover slips.
Wound healing assay. Cell migration was measured using 
an in vitro wound healing assay. OV2008 and C13 cells were 
allowed to form a confluent monolayer in modified 35-mm 
tissue culture dishes until confluent. The wound was created 
by scraping monolayer cells with a sterile pipette tip to scratch 
a ʻwoundʼ into the confluent monolayer. The media was 
changed to remove debris and cells. The dish was placed into 
a stage top incubation LiveCell device (Pathology Devices, 
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Exton, PA). The LiveCell device maintained the temperature 
at 37˚C, the CO2 at 5%, and the relative humidity at 75% within 
the stage top chamber. Slidebook software was used to take 
a picture at time point zero and every 10 min for a total of 
10 h using an Olympus IX70 inverted microscope (Center 
valley, PA). TScratch software (developed by Tobias Gebäck 
and martin Schulz, ETh zürich) was used to analyze the 
images, measuring the differences in migration. Values are 
presented as percentage (%) of open area (ʻwoundʼ) remaining 
at 10 h compared to 0 h. The time lapse stacks of images were 
also analyzed using ImageJ and the two following plug-ins: 
i) Manual Tracking (developed by Fabrice Cordeli, Institute 
Curie, Orsay, France) and ii) Chemotaxis and Migration Tool 
(Ibidi, martinsried, Germany). Individual cells were randomly 
selected and tracked throughout the 10-h time period, as 
demonstrated in Fig. 1.
Migration assay. OV2008 and C13 cells were grown in 35-mm 
tissue culture dishes until confluent. Cells were then trypsinized 
and migration assays were performed using ThinCerts migra-
tion inserts with 8 µm pore size (bioexpress, kaysville, UT). 
Briefly, 2x105 cells suspended in 200 µl of serum-free RPmI 
were added to the upper compartment of the insert, which rests 
in the well of a 24-well plate. RPMI (650 µl) containing 10% FBS 
was added to the bottom compartment with serum providing the 
chemoattractant signal. The cells were cultured at 37˚C and 5% 
CO2 and allowed to migrate for 24 h. The inserts were removed 
and the remaining non-migrating cells on the upper surface 
of the membrane were removed with a cotton swab. The cells 
that migrated to the lower surface of the membrane were fixed 
with 4% formaldehyde for 5 min at room temperature, washed 
twice with PbS and stained with harris hematoxylin Solution 
(Sigma-Aldrich) for 45 min at room temperature. Inserts were 
washed several times with tap water until the membrane was 
clean. The membrane was peeled off the plastic inserts, placed 
on glass microscope slides and mounted using HistoChoice 
mounting media (Amresco, Solon, OH).
Migrating cells were examined by microscopy at x200 
magnification with Olympus IX70 microscope. Pictures were 
taken of 5 randomly chosen different fields and migrating cells 
were counted manually. The average of number of migratory 
cells for each condition was calculated and the differences in 
the number of cells that migrated through the membrane were 
calculated.
Western blot analysis. Cells were grown until approximately 
90% confluent and washed twice in cold PbS. Cells were 
lysed on ice, using RIPA buffer (1% NP40, 0.5% Na deoxy-
cholate, 0.1% SDS, 150 mM NaCl) containing Halt Protease 
Inhibitor Single-Use Cocktail (100X) (Pierce, Rockford, IL). 
The protein concentration in these whole cell lysates was 
measured using the bicinchoninic acid (BCA) Protein Assay 
(Pierce) and calculated based on the bSA standard curve. 
Protein (50-80 µg) was prepared for SDS-PAGE by denaturing 
the lysate in 6X loading buffer containing β-mercaptoethanol 
and DTT followed by boiling for 5 min. Protein preparations 
were loaded into 10% SDS-PAGE gels and run for 90 min at 
150 V. Proteins on the gel were transferred onto nitrocellulose 
membrane (bio-Rad, hercules, CA) for 1 h at 110 v, followed 
by washing 3 times in TBS with 0.1% Tween-20. Membranes 
were blocked in TTbS with 5% non-fat dry milk for 45 min and 
then incubated overnight at 4˚C with polyoclonal antibodies 
in primary antibody diluent solution from the SuperSignal 
Western Blot Enhancer kit (Thermo Scientific) containing 
either anti-PAk2 or anti-β-actin (Cell Signaling Technologies, 
Danvers, mA). membranes were washed 3 times in TTbS and 
incubated for 1 h at room temperature with the appropriate 
HRP-conjugated secondary antibody (anti-mouse for β-actin, 
Santa Cruz Biotechnology, Inc.; anti-rabbit for PAk2, Santa 
Cruz Biotechnology, Inc.). Membranes were washed three 
times in TTBS and developed by ECL western blotting detec-
tion system from Santa Cruz Biotechnology, Inc. Finally, 
chemiluminescence was detected via exposure to hyblot CL 
autoradiography film (Denville Scientific, Metuchen, NJ). 
Digital images of the membranes were scanned and bands 
intensities were quantified using ImageJ analysis.
Small interfering RNA transfections. For the wound healing 
assays, OV2008 and C13 cells were grown in modified 35-mm 
tissue culture dishes until 50-60% confluent. Cells were trans-
fected with 10 µl of TransIT-TKO transfection reagent (Mirus 
Bio LLC, Madison, WI) and either 50 nM non-targeting 
control siRNA or 50 nM SignalSilence PAk2 siRNA (Cell 
Signaling Technology). The siRNA sequences are proprietary. 
The transfection was performed in antibiotic-free media and 
the cells were incubated for 24 h before changing the media. 
When the cells reached confluence (usually one additional 
day) the wound was created with a 10-µl pipette and time point 
zero was photographed with the IX70 microscope. Cells were 
then incubated for 20 h at 37˚C and 5% CO2 until time point 
20 h was then captured. mock transfection with TransIT-TkO 
reagent alone revealed that the transfection process decreased 
cell movement in general. Therefore longer time periods were 
used to assess wound healing and migration assays post-
transfection.
For the migration assays, cells were first plated in 35-mm 
dishes and allowed to attach overnight. The next day, cells 
were transfected with either control siRNA or PAk2 siRNA. 
The media was changed after 24 h of incubation. Forty-eight 
hours post-transfection, the cells were trypsinized, counted 
Figure 1. Tracking of individual cell movement during in vitro time-lapse 
recorded wound healing assay.
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and seeded into the inserts as described above. Cells were 
allowed to migrate for 48 h before the inserts were stained, 
washed and mounted on slides as described above.
Microarray. Cells were plated and cultured on uncoated, 
fibronectin-coated or collagen I-coated glass cover slips 
for 24 h. Total RNA of the cells was then isolated using the 
RNeasy Mini kit (Qiagen). RNA yield was determined using 
the ND-1000 spectrophotometer (NanoDrop). The Ambion 
WT Expression kit (Ambion) was used to synthesize first-
strand cDNA from the isolated RNA. Next, a template for 
transcription was created by synthesizing second-strand 
cDNA. Antisense cRNA was synthesized and amplified 
by in vitro transcription in a thermal cycler (Eppendorf 
Mastercycler Gradient). The resulting cRNA was purified 
using nucleic acid binding beads. Next, second cycle cDNA 
was synthesized by the reverse trans cription of cRNA using 
random primers before hydrolyzing the cRNA template with 
RNase H. Second-cycle cDNA was purified using nucleic 
acid binding beads before the yield was determined using 
the ND-1000.
The second-cycle cDNA was fragmented and labeled 
using the GeneChip WT Terminal Labeling kit (Affymetrix). 
The fragmented and labeled DNA samples were hybridized 
to a GeneChip Human Gene 1.0 ST Array cartridge for 17 h 
at 45˚C at 60 rpm in a GeneChip Hybridization Oven 640 
(Affymetrix). The chips were then stained and washed using 
the GeneChip hybridization, Wash and Stain kit (Affymetrix) 
and a GeneChip Fluidics Station 450 (Affymetrix). Finally, 
the chips were scanned using the Affymetrix GeneChip 
Scanner 3000 using Affymetrix GeneChip Command 
Console software. The resulting cell files were analyzed 
using BRB-ArrayTools developed by Dr Richard Simon and 
bRb-ArrayTools Development Team. JmP Genomics Suite 
6.0 was also used to analyze and graph the results.
Statistical analysis. means derived from multiple treatments 
in the two ovarian cancer cell lines were analyzed by one way 
analysis of variance (ANOVA) using SPSS, version 20. Tukey 
and LSD were the two post-hoc tests used. In all cases, p<0.05 
was considered significant.
Results
Migration of OV2008 and C13 cells. Migration through the 
porous membrane of transwell inserts was used to measure 
3-D motility of the selected cell lines. more than 3 times as 
many OV2008 cells migrated through the cell culture insert 
membranes than C13 cells over a 24-h period and the differ-
ence was significant (Fig. 2).
Removing cells from a confluent culture creates a scratch 
wound (Fig. 3A). Although the overall area of the wound 
is slightly greater for OV2008 cells, the wound is almost 
completely closed 10 h post-wounding, whereas the wound for 
the C13 cells remained substantially open during the same time 
period. Thus, the OV2008 cells had a much greater capacity 
to heal a scratch wound than the C13 cells when cultured on 
untreated glass cover slips (Fig. 3B). When the amount of 
wound remaining open 10 h post-wounding was compared 
as a percentage of the area of the original wound (0 h), there 
was over 3-fold more open wound area remaining in C13 than 
OV2008 cells (Fig. 3A).
In order to determine if the wound was being closed due 
to cell movement into the wound, individual cells randomly 
selected along the border of the wounds were tracked in each 
frame of the time-lapse recordings. Inspection of the time 
lapse recording reveals that the OV2008 cells do migrate into 
the open area to heal the wound whereas the C13 cells do 
not generally move into the wound. Somewhat surprisingly, 
both cell lines have highly motile cells. The OV2008 cells 
primarily moved perpendicular to the edges of the wound 
into the open area to effectively close the wound. In contrast 
to the Ov2008 cells, the C13 cells did not move towards the 
open area, rather C13 cells tended to move parallel to the 
wound edges and to often change direction. Although the C13 
cells were motile, the cell movement did not result in wound 
closure. When the trajectory of cells was plotted on a polar 
coordinate grid (Fig. 4), a directionality index (Euclidean 
distance/total distance moved) can be developed where an 
index of 1.0 represents completely directional movement in 
a straight line perpendicular to the wound edge and an index 
of 0.0 represents totally random cell movement. There is a 
1.3-fold greater tendency of the OV2008 cells to move in a 
directional fashion than for C13 cells. Thus, as measured by 
two different motility assays, Ov2008 cells appear to have a 
greater capacity for directional movement as compared to the 
C13 cell line.
Collagen type I enhances the migration of ovarian cancer 
cells. The effect of collagen I on the migratory behavior of the 
OV2008 and C13 cells plated on collagen I-coated cover slips 
is illustrated in Fig. 5. Although there was a slight decrease 
in the amount of wound remaining open 10 h post-wounding 
when compared as a percentage of the area of the original 
wound (0 h) for cells plated on collagen I compared to cells 
plated on glass for the OV2008 cells, the difference was not 
significant. In contrast, collagen I significantly increased total 
wound healing motility in C13 cells such that only about 10% 
of the wound area remained open. Furthermore, there was no 
longer a wound healing difference between the two cell lines 
and thus collagen I makes the two cell lines phenotypically 
similar in regard to migratory capacity.
Figure 2. OV2008 cells migrate better through an uncoated 8 µm porous mem-
brane than their cisplatin-resistant sister cell line, C13. values are presented as 
% of open area and represent the mean ± SEM; OV2008 n=9, C13 n=5.
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Analysis of time lapse recordings for directional cell move-
ment demonstrates that as with wound healing, collagen I did 
not alter the directionality of OV2008 cells during wound 
healing (Fig. 6). In contrast, the directionality of individual 
cells during wound healing was increased in C13 cells by 
collagen I as compared to glass (Fig. 6A) as was the direc-
tionality index (Fig. 6B). Thus collagen I allows C13 cells to 
express a migratory behavior similar to that of OV2008 cells.
Fibronectin reduces the migratory capacity of OV2008 cells. 
OV2008 and C13 cells cultured on fibronectin-coated cover 
slips move differently than on those coated with collagen I. 
In contrast to collagen I, fibronectin significantly reduced 
OV2008 total wound healing motility as illustrated in Fig. 7 
and there was essentially no effect of fibronectin on C13 total 
wound healing motility. So, OV2008 cells cultured on fibro-
nectin-coated glass appeared to express a phenotype similar to 
C13 cells migrating on uncoated glass or fibronectin.
In terms of directionality as determined from time lapse 
microscopy, the effect of fibronectin was opposite of that for 
collagen I, such that the directionality of C13 cells was not 
changed when the cells were cultured on fibronectin and the 
Figure 3. OV2008 cells heal a scratch wound better than the C13 cells on uncoated glass cover slips. (A) Scratch wound assay for OV2008 and C13 ovarian 
cancer cell lines. Cells were plated on glass cover slips for 24 h prior to scratch wounding to remove cells. The cells were cultured for an additional 10 h and 
monitored with time-lapse microscopy. The images are representative samples of images obtained at 0 and 10 h after the scratch. (B) Migratory capacity 
of OV2008 and C13 cells. Wound healing assay was performed 24 h after cells were seeded on glass cover slips. Migration potential was measured by 
scratching the confluent monolayer and observing the movement of cells into the gap. Values are presented as % of open area and represent the mean ± SEM; 
OV2008 n=4, C13 n=3.
Figure 4. Directionality of OV2008 and C13 cells cultured on glass. (A) Cells were tracked every 10 min from 0-10 h post-wounding and their paths overlayed 
on a polar grid. Paths are oriented such that the start point is normalized to the origin and the wound face runs parallel to the y-axis. Each plot represents 
10 individual cell tracks from 3 separate experiments (30 total cell tracks). (b) Directionality Index (Euclidean Distance/Accumulated Distance) of Ov2008 
and C13 cells. Values represent the mean ± SEM, n=30.
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directionality of individual cells during wound healing was 
decreased for OV2008 cells by fibronectin as compared to 
glass (Fig. 8).
In addition to the effect of collagen I and fibronectin 
on wound healing and directionality, migration across a 
membrane was effected. There was a significant 65% reduc-
tion in the number of OV2008 cells that migrated through 
the fibronectin-coated membrane than through the uncoated 
membranes as illustrated in Fig. 9. There was no effect of the 
fibronectin coating on migration of C13 cells through the insert 
Figure 5. Culturing cells on collagen I increases migration in OV2008 and 
C13 cell lines. Wound healing assay was performed 24 h after cells were 
seeded on uncoated or collagen I-coated cover slips. Migration potential 
was measured by scratching the confluent monolayer and observing the 
movement of cells into the gap. Cells cultured on glass showed a greater 
open wound area compared with cells grown on collagen I at 10 h after the 
wound was made. values are presented as % of open area and represent the 
mean ± SEM; OV2008 n=4, C13 n=3.
Figure 6. Directionality of OV2008 and C13 cells cultured on glass and collagen I. (A) Cells were tracked every 10 min from 0-10 h post-wounding and their 
paths overlayed on a polar grid. Paths are oriented such that the start point is normalized to the origin and the wound face runs parallel to the y-axis. Each plot 
represents 10 individual cell tracks from 3 separate experiments (30 total cell tracks). (b) Directionality Index (Euclidean Distance/Accumulated Distance) of 
OV2008 and C13 cells on glass and collagen I. Values represent the mean ± SEM, n=30.
Figure 7. Culturing cells on fibronectin decreases migration in OV2008 but not 
C13 cells. Wound healing assay was performed 24 h after cells were seeded on 
uncoated or collagen I-coated cover slips. Migration potential was measured 
by scratching the confluent monolayer and observing the movement of cells 
into the gap. OV2008 cells cultured on fibronectin showed greater open wound 
area compared with cells cultured on glass at 10 h after the wound was made. 
Wound healing of C13 cells was not affected by the presence of exogenous 
fibronectin. Values are presented as % of open wound area and represent the 
mean ± SEM; OV2008 n=4, C13 n=3.
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membranes. In contrast and consistent with the effect observed 
in the wound healing assays, collagen type I increased the 
migration of the cells through the culture insert membranes 
such that there was a 2.3-fold increase in the number of C13 
cells that migrated through the collagen I coated membranes 
than through the uncoated membranes as illustrated in Fig. 9. 
Although not statistically significant, there also was a 1.7-fold 
increase in the number of OV2008 cells migrating through 
the collagen I coated membranes. Thus, two different motility 
assays showed that fibronectin decreases and collagen I 
increases the migratory ability of the OV2008 and C13 cells.
Identification of relevant genes. Exploratory analyses of gene 
expression in cells expressing the different cell movement 
phenotypes observed when the cells were cultured on glass, 
collagen I or fibronectin, were performed for each of the 
cell lines for each of the above conditions. Treatments were 
divided by phenotype into two groups: motile/directional cells 
(OV2008-Glass, OV2008-Collagen, C13-Collagen) and the 
Figure 8. Directionality of OV2008 and C13 cells cultured on glass and fibronectin. (A) Cells were tracked every 10 min from 0-10 h post-wounding and their 
paths overlayed on a polar grid. Paths are oriented such that the start point is normalized to the origin and the wound face runs parallel to the y-axis. Each 
plot represents 10 individual cell tracks from 3 separate experiments (30 total cell tracks). Cells tracks were recorded using ImageJ and the following plug-ins: 
Manual Tracking, Ibidis Chemotaxis and Migration Tool. (B) Directionality Index (Euclidean Distance/Accumulated Distance) of OV2008 and C13 cells on 
glass and fibronectin. Values represent the mean ± SEM, n=30.
Figure 9. Culturing cells on collagen I and fibronectin affects migration in 
Ov2008 and C13 cells. Cells (2x105) were placed in the upper chamber of 
uncoated, collagen I-, or fibronectin-coated membranes and allowed to migrate 
for 24 h. Cells that migrated from the upper to the lower chamber were stained 
with hematoxylin and pictures taken with Olympus Ix70 microscope. Cells 
from 5 different fields/images were counted from 3 different experiments and 
data are presented as average number of migratory cells. Values represent the 
mean ± SEM, n=5.
Figure 10. Overlay plot of gene expression grouped by phenotype (more 
motile cells are blue = OV2008-Glass, C13-Coll-I, OV2008-Coll I; less 
motile cells are red = C13-Glass, OV2008-FN, C13-FN).
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less motile/less directional cells (C13-Glass, C13-Fibronectin, 
Ov2008-Fibronectin) and it was apparent that there was 
differential expression of several genes known to play a role 
in cell motility. Treatments were divided by phenotype into 
two groups (Fig. 10): motile cells (OV2008-Glass, OV2008-
Collagen, C13-Collagen) and the less motile cells (C13-Glass, 
C13-Fibronectin, Ov2008-Fibronectin).
PAK2 inhibition and knockdown reduces the ability of ovarian 
cancer cells to migrate. Among the candidate shown in Fig. 10, 
p21-activated kinase 2 (PAK2) provided tight grouping and 
distinct separation of the motility phenotypes and has been 
reported to be either upregulated or hyperactivated in a variety 
of human cancers. In order to determine the role of PAk in 
the migratory changes that were observed when the cells were 
grown on collagen type I, both the OV2008 and C13 cells were 
pretreated with the PAK inhibitor, IPA-3, that targets the auto-
regulatory mechanism of group I PAKs. When C13 cells were 
cultured on collagen I and treated with increasing concentra-
tions of the PAk inhibitor (IPA-3) for 2 h prior to the wound 
healing assay, there was a dose-dependent response such that 
there was increase in the percent of open wound area with 
an increasing inhibitor concentration (Fig. 11A). There was a 
similar effect on wound healing in OV2008 cells cultured on 
collagen I and treated with increasing concentrations of IPA-3.
As shown in Fig. 11B, when C13 cells were cultured on 
collagen I and treated with increasing concentrations of IPA-3 
for 2 h prior to the wound healing assay, there was also a 
dose-dependent response in terms of individual cell direction-
ality. Directionality of Ov2008 cells was similarly affected. 
Thus, inhibition of PAk prevented the motility/directionality 
promoting effect of collagen I on cells.
Since there appeared to be an effect of IPA-3 inhibition on 
both OV2008 and C13 cell migration, siRNA transfection was 
Figure 11. Effect of IPA-3 on wound healing and directionality of OV2008 
and C13 cells. Group I PAk inhibition decreases OV2008 and C13 migration 
potential on collagen I. (A) Wound healing assay was performed 2 h after 
treatment with IPA-3 at the indicated concentrations. Migration potential was 
measured by scratching the confluent monolayer and observing the movement 
of cells into the gap. Cells treated with IPA-3 showed more open wound area 
compared with untreated cells at 10 h after the wound was made. values are 
presented as % of open area. (B) Confluent monolayers of cells were treated 
with the indicated concentration of IPA-3 2 h prior to wounding. Cells were 
tracked every 10 min from 0-10 h post-wounding and directionality was cal-
culated by comparing the Euclidean and accumulated distances of the cells. 
Values represent the mean ± SEM, n=30.
Figure 12. Specific knockdown of PAk2 using siRNA transfection reduces 
both wound healing ability and directionality of migrating ovarian cancer 
cells. (A) Western blotting was used to verify that PAk2 protein was effectively 
knocked down following transfection with PAk2 siRNA. (B) Wound healing 
assay was performed 24 h after cells were seeded on collagen I-coated cover 
slips. Cells transfected with PAk2 siRNA showed a greater open wound area 
compared with cells transfected with control siRNA at 20 h after the wound 
was made. Values are presented as % of open area, n=3 (C) Directionality 
Index (Euclidean Distance/Accumulated Distance) of Ov2008 and C13 cells 
post-transfection. Values represent the mean ± SEM, n=30.
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used to specifically inhibit the PAk2 isoform of PAk prior to 
wound healing assays on collagen I-coated coverslips. Western 
blotting was used to verify that PAk2 protein was effectively 
knocked down following transfection with PAk2 siRNA 
(Fig. 12A). When the mean amount of wound remaining 
open 20 h post-wounding was compared as a percentage of 
the area of the original wound (0 h), there was a significant 
4-fold greater open wound area remaining in OV2008 cells 
receiving PAk2 siRNA than the cells receiving control siRNA 
(Fig. 12B). Although there was a similar 4-fold greater open 
wound area remaining in C13 cells receiving PAk2 siRNA 
than the cells receiving control siRNA, the difference did 
not achieve statistical significance (Fig. 12B). Additionally, 
transfection with PAk2 siRNA significantly decreased the 
ability of Ov2008 cells to move in a directional manner on 
collagen I (Fig. 12C). However, the directionality of C13 cells 
on collagen I was not affected by PAk2 knockdown.
Discussion
The current studies investigated the motility characteristics 
of two related ovarian cancer cell lines (Ov2008 and C13) 
and found that OV2008 cells had a much greater capacity to 
migrate through a porous membrane of a transwell insert and 
heal a scratch wound when cultured on glass than the C13 cells. 
Furthermore, the studies indicate that wound healing is due 
to characteristics associated with cell movement rather than 
cell proliferation and specifically attributable to a difference 
in directionality as opposed to differences in the total distance 
that the cells moved. These differences were unexpected 
because the C13 cells were selected to have reduced chemo-
sensitivity via a series of in vitro cisplatin challenges of the 
parental OV2008 cell (23) with no attention given to changes 
in motility. In subsequent experiments, these differences in 
cell motility could be negated or exaggerated by culturing the 
cells on one ECm substrate versus another.
Culturing cells on collagen I coated cover slips or 
transwell membranes increased total wound healing and 
individual cell directionality, as well as migration through 
a porous membrane for both cell lines with the effect being 
the most dramatic on the migration of C13 cells. While the 
two cell lines migrated differentially on uncoated glass, they 
become phenotypically similar when plated on collagen I 
coatings. These findings are consistent with previous reports 
in the literature which used collagen I as a chemo- and hapto-
tactic attractant for ovarian cancer cells. Recently, Shen et al 
(24) observed that ovarian cancer cells demonstrate enhanced 
migration through a collagen type I-coated transwell inva-
sion assay. Similarly, Ahmed et al (25) showed that collagen I 
enhanced the migration of ovarian cancer cell lines through 
a Boyden chamber when collagen I was used as a chemo-
attractant in the lower part of the chamber as well as when 
it coated the upper part of the chamber. The current studies 
confirm these findings and further reveal that the effect of 
collagen type I on the migration of ovarian cancer cells is 
at least in part due to an increase in directionality. Although 
the complex process of cellular motility is well studied and 
it is known that cells must polarize, protrude, adhere and 
reorganize the cytoskeleton in order to move, it is not clearly 
understood how the basic motility machinery is coupled to 
a steering mechanism that integrates environmental cues 
such as ECM (26). By showing in the present investigation 
that collagen I provides ʻsteeringʼ cues to migrating ovarian 
cancer cells, we can better understand how collagen type I 
facilitates cancer cell movement.
Understanding the effect of collagen type I is important 
because ovarian tumor cells have been shown to attach prefer-
entially at locations where the mesothelium is disrupted and 
the underlying collagen I-rich stromal matrix is exposed (27). 
Collagen type I is abundant in the interstitial matrix and there-
fore is a substrate that ovarian cancer cells disseminated to the 
peritoneal cavity will inevitably encounter upon attachment 
and exposure to the submesothelial ECM during invasion (28). 
moser et al (29) demonstrated that ovarian carcinoma cells 
adhere preferentially to type I collagen and Burleson et al 
(28) reported that ovarian cancer spheroids can completely 
disaggregate on type I collagen coatings. Both of these studies 
examined disaggregation of cells from spheroids on collagen 
type I, so the effect of collagen I on cell motility was only indi-
rectly inferred, whereas the current studies tracked individual 
cells and provide direct measures of distance and direction for 
cell movement in response to being cultured on collagen I.
In contrast to the effects of collagen I on cell movement, 
in the current investigation fibronectin (FN) reduced the 
migration of OV2008 cells as measured by two different 
migration assays. While the two cell lines migrated differenti-
ally on uncoated glass, they become phenotypically similar 
when plated on fibronectin coatings, adopting the movement 
characteristic of C13 on glass. That is, the cells migrate less 
directionally on FN than on collagen type I or uncoated glass. 
Fibronectin is another important constituent of the ECm at 
the metastatic site of ovarian cancer. mesothelial cells express 
fibronectin on the apical surface and soluble FN has been 
detected in the ascities fluid from ovarian cancer patients. 
However, the impact of fibronectin on ovarian cancer cells 
is less clear than that of collagen I with evidence for both 
increased and decreased movement in association with FN. It 
has been reported that FN released by peritoneal mesothelial 
cells stimulates ovarian cancer cell motility (30). In a study 
by Ahmed et al (25), fibronectin increased the migration of 
ovarian cancer cells through a Boyden chamber when used as 
a chemoattractant in the lower part of the chamber. Fibronectin 
has been reported to increase the migration of pancreatic (31) 
and breast cancer (32) cells as well. On the other hand, there is 
evidence indicating that metastatic potential is inversely corre-
lated with FN expression (33,34). Also, a correlation between 
the loss of FN and acquisition of the malignant phenotype 
in vitro and of tumorigenic and metastatic phenotypes in vivo 
has been reported (35,36).
It is possible that migration on fibronectin is medi-
ated by other proteins that are differentially expressed in 
Ov2008 and C13 cells. Jiao et al (37) recently showed that 
human melanoma cell migration on fibronectin was greatly 
decreased when matrix metallopeptidase-2 (mmP-2) activity 
was inhi bited. The authors (37) suggested that active MMP-2 
is recruited to the leading edge of invasive tumor cells and 
cleaves fibronectin into shorter fibronectin products. The 
fibronectin fragments promote αvβ3 integrin recruitment to 
the area of cleaved fibronectin products to facilitate tumor cell 
adhesion and migration. Interestingly, MMP-2 was identified 
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in the current investigation via microarray as being expressed 
higher in the more motile cells than in the less motile cells 
and the expression was decreased by FN in both cell lines. 
An elegant study by Kenny and Lengyel (38) used several 
different models to examine the expression of mmP-2 in 
ovarian cancer cells. In one model, a novel organotypic 3D 
coculture model mimicking human omentum was created 
using collagen I, human primary mesothelial cells (HPMCs), 
and human primary fibroblasts (HPFs) that were extracted 
from human omentum. The relative expression of mmP-2 
mRNA was 20-fold higher in ovarian cancer cells attached 
to the 3D coculture than in ovarian cancer cells adhering to 
plastic. Thus it is possible that in the current study that the 
differential expression of MMP-2 influenced the ability of 
cells to interact with the FN and their ability to migrate on 
fibronectin-coated surfaces.
The results of the migration assays in the present investi-
gation clearly demonstrated that collagen I and fibronectin 
modify the migratory process of ovarian cancer cells and 
microarrays were used to study gene expression patterns and 
narrow down the list of possible mediators. When comparing 
the gene expression profiles of OV2008 and C13 cells grown 
on glass, collagen I and fibronectin, a relatively short list of 
candidate genes was established. Among the candidates, 
p21-activated kinase has been reported to be either upregulated 
or hyperactivated in a variety of human cancers such as breast, 
ovary, colorectal, thyroid and pancreatic (21). In addition, it is 
activated by the Rho family GTPases Cdc42, Rac and Rho, 
which are activated in response to ECm adhesion (39).
Initial screening for the role of PAKs in mediating direc-
tional movement of Ov2008 and C13 cells was accomplished 
using the group I PAK (PAK1, PAK2, PAK3) chemical 
inhibitor, IPA-3 which was first identified as a highly selective 
inhibitor of group I PAK kinases by testing its effect on over 
200 different kinases (40). It was reported that this selectivity 
was achieved by targeting the distinct autoregulatory mecha-
nism conserved in group I PAKs (40). In the present study, 
inhibition of group I PAKs with IPA-3 resulted in decreased 
total wound healing and directionality of OV2008 and C13 
cells grown on collagen I and confirmed a role for one or 
more of the group I PAKs. While a majority of the literature 
is focused on the PAk1 isoform, both PAk1 and PAk2 have 
been implicated in cell motility. Coniglio et al (41) reported 
that PAk2 was needed to generate new focal adhesions and 
to limit the sizes of focal adhesions in breast cancer cells. In 
prostate cancer cells, Bright et al (42) observed that both PAk1 
and PAk2 affected migration speed. Knockdown of PAk1 and 
PAk2 in ovarian cancer cell lines reduced cell migration and 
invasion (43). PAk2 has also been implicated in the migration 
of hepatocellular carcinoma cells (44) and monocytes (45). 
In order to specifically assess the role of the PAk2 isoform, 
which was identified as a candidate in the microarray experi-
ments, knockdown of PAk2 with an isoform specific siRNA 
sequence was performed and resulted in decreased overall cell 
migration as well as decreased directionality of individually 
migrating cells.
PAk2 appears to play a role in generating new focal 
adhesions as well as limiting the sizes of focal adhesions. 
PAk2-depleted breast cancer cells contain significantly larger 
focal adhesions and are unable to generate new focal adhe-
sions (41). During cell migration, the assembly, maturation, 
translocation and disassembly of focal adhesions mediate, 
respectively, cell attachment, contraction, protrusion of leading 
edges and retraction of trailing edges (46). Therefore, by 
controlling the generation and size of focal adhesions, PAk2 
may play an important role in the regulation of cell migra-
tion. Thus the loss of general movement and directionality in 
cells that were transfected with PAk2 siRNA could be due 
to unrestricted, large focal adhesions anchoring the cells to 
the substrate which would prevent any movement of the cells. 
Another of our candidate genes, talin-1 (TLN1), would be 
worthy of investigation in the future. TLN1 has been shown 
to play important roles in adhesion, cytoskeletal organization 
and regulation of integrin signals during cell migration (47).
In the traditional analysis of wound healing assays, the 
width of a scratch is compared at time point 0 to that at the end 
of the experiment. When the wound has not healed, the cells 
are assumed to not have migrated (48). However, time lapse 
microscopy revealed that even when the cells were not healing 
the wound, they were indeed moving. By tracking individu-
ally migrating cells, we were able to measure the distance and 
direction of the cells moved and show that collagen I has 
the ability to direct cell movement into the wound and thus 
promote healing. In contrast, fibronectin was able to decrease 
directionality in OV2008. Directed cellular migration is 
important in facilitating the coordinated movement of cells 
throughout development and in wound repair (49). Directional 
movement may also affect the ability of metastasizing ovarian 
cancer cells to colonize the peritoneal microenvironment. The 
ability of fibronectin to inhibit metastasis in some studies may 
be in part to the effect on directionality. Finally, our results also 
suggest that the use of PAK inhibitors should be explored for 
possible use in conjunction with tumor debulking to limit the 
spread of ovarian metastases throughout the peritoneal cavity.
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